GMR SOLUTIONS INC (GMRS)
NYSEIndustrialsMedical - Care FacilitiesSnapshot 2026-10-16
NYSEIndustrialsMedical - Care FacilitiesSnapshot 2026-10-16
Research Workspace
Put GMRS beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Industrials is in expansion. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Management is running behind on a stated commitment.
View ThesisExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationThis stock is volatile — it swings about 2% on a typical day and fell roughly 40% in its worst 12-month stretch.
View RiskGMRS depends on steady revenue growth and lower debt costs to support its earnings goals. Revenue grew 3.3% year over year, while Q2 FY2026 missed consensus. No clean valuation multiple is available, so the price-versus-peer comparison is unclear. The next-quarter miss probability is 56%, and management is behind on a stated commitment. Peer multiples imply no available price comparison; the thesis is on watch. This read is provisional.
Trailing returns as of 2026-10-16. GMRS is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 8 analysts currently covering GMRS (as of Oct 2026).
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
Continue this research
Compare GMRS with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| GMRS Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 0 valuation methods, at three horizons. As of 2026-10-16. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Health Care Facilities — fair value, gap to price, and forward P/E.
Compare the value case
Put GMRS next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Reduce leverage and strengthen balance sheet through debt repayment
Interest savings support debt repayment and balance sheet strengthening.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-16. EPS is implied from price ÷ P/E. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.

Advances: Reduce leverage and strengthen balance sheet through debt repayment
Reduces leverage and strengthens balance sheet through lower interest costs.

Advances: Deliver adjusted EBITDA between $1.135B and $1.195B in 2026
Lower interest rates improve adjusted EBITDA potential.

New board members enhance leadership and strategic direction.

New board members enhance leadership and strategic direction.
